Company Encyclopedia
View More
name
Erasca
ERAS.US
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
1.945 T
ERAS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Erasca (NASDAQ:ERAS) Sets New 52-Week High - What's Next?

    Erasca (NASDAQ:ERAS) reached a new 52-week high at $3.38, closing at $3.29 with a 13.8% increase. Analysts have mixed ratings: Morgan Stanley and Bank of America issued lower price targets, while Guggenheim raised its target to $5.00 with a "buy" rating. Institutional investors have increased their stakes, owning 67.78% of the stock. Erasca focuses on precision oncology therapies, with its lead product in phase 1b trials. Despite a "Hold" rating, analysts suggest other stocks may be better investments.

    Market Beat·
    US
    ERAS
    +2.51%
    Market Beat·
    US
    ERAS
    +2.51%

    The Nasdaq Biotechnology Index closed up over 1.9%. Anavex Life Sciences rose 24.93%, Fortrea Holdings rose 16.16%, Erasca rose 14.53%. Regeneron Pharmaceuticals fell 2.69%, Aurinia Pharmaceuticals fell 6.85%, NewAmsterdam Pharma fell 8.71%, Adaptive Biotechnologies fell 8.83%

    Wallstreetcn·
    US
    AVXL
    -1.12%
    US
    ERAS
    +2.51%
    Wallstreetcn·
    US
    AVXL
    -1.12%
    US
    ERAS
    +2.51%

    Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results

    Guggenheim’s analyst Michael Schmidt reiterated a “Buy” rating for Erasca, Inc. (NASDAQ:ERAS) with a $5 price target, following the company’s Q3 2025 results. Key drivers include recent Phase 1 trial initiations.

    MSN·
    US
    ERAS
    +2.51%
    MSN·
    US
    ERAS
    +2.51%

    Erasca to Present at the 8th Annual Evercore Healthcare Conference | ERAS Stock News

    Erasca, Inc., a clinical-stage precision oncology company, announced its participation in the 8th Annual Evercore Healthcare Conference on December 3, 2025. The event will include a fireside chat and one-on-one investor meetings, with a live webcast available online. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer through novel therapies and combination regimens.

    StockTitan·
    US
    ERAS
    +2.51%
    StockTitan·
    US
    ERAS
    +2.51%

    H.C. Wainwright Remains a Buy on Erasca (ERAS)

    H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Erasca with a $6.00 price target. Stifel Nicolaus also maintained a Buy rating with the same price target. Maldonado, who covers the Healthcare sector, has an average return of 17.5% and a 51.92% success rate on recommended stocks.

    Tip Ranks·
    US
    ERAS
    +2.51%
    Tip Ranks·
    US
    ERAS
    +2.51%
    © 2025 Longbridge｜Disclaimer